Analysis of 6,135 children with juvenile idiopathic arthritis found that antibiotic exposure in the 10 months before starting methotrexate had no effect on treatment response. Children with prior antibiotic use were equally likely to require a second disease-modifying drug as those without exposure, with adjusted hazard ratios of 1.01 for methotrexate users and 1.10 for TNF inhibitor users. This finding challenges assumptions about microbiome disruption undermining autoimmune treatment efficacy. The gut microbiome's role in drug metabolism and immune regulation has garnered significant attention, particularly after studies in rheumatoid arthritis suggested antibiotic-induced dysbiosis could impair methotrexate response. However, this pediatric population may have more resilient microbiomes or different inflammatory pathways than adults. The reassuring results are clinically relevant given that children with autoimmune conditions face elevated infection risks and frequently require antibiotics. While the study's observational design and reliance on insurance claims data limit causal inference, the large sample size and consistent results across antibiotic types and timing provide robust evidence that pre-treatment antibiotic exposure shouldn't influence DMARD selection decisions in pediatric rheumatology practice.